INNOVACAP2024-10-012024-12-31 INNOVACAP2024-10-012024-12-31 INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses04Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses05Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses06Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses07Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses08Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses09Member INNOVACAP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses10Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses04Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses05Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses06Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses07Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses08Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses09Member INNOVACAP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses10Member INNOVACAP2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544067 INNOVACAP NOTLISTED Innova Captab Limited Equity 2024-04-01 2025-03-31 2025-02-05 2025-01-29 INR Millions Third quarter 14:30:00 15:53:00 2025-02-05 2025-02-05 Not applicable Single segment Drugs and Pharmaceutical products 2024-10-01 2024-12-31 Unaudited Consolidated 3164620000.00 43250000.00 3207870000.00 1957610000.00 111840000.00 29830000.00 282090000.00 1660000.00 51320000.00 317640000.00 2751990000.00 455880000.00 0.00 455880000.00 76860000.00 36980000.00 113840000.00 0.00 342040000.00 0.00 0.00 0.00 0.00 342040000.00 -300000.00 341740000.00 0.00 0.00 0.00 0.00 572250000.00 10 5.97 5.97 0.00 0.00 5.97 5.97 1. The above consolidated financial results of Innova Captab Limited ( the Company ) have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ( the act ) read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. 2. The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 05 Feburary 2025. The Board of Directors at their meeting held on 05 Feburary 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter and nine months ended 31 December 2024. 3. The Company has only one reportable segment i.e.“Drugs and pharmaceutical products” as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. 4. The Group acquired Sharon Bio-Medicine Limited as on 30 June 2023. Accordingly, the statement of unaudited consolidated financial results includes the financial results of the Sharon Bio-Medicine Limited from 01 July 2023. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 9289350000.00 86650000.00 9376000000.00 5888950000.00 339230000.00 -67440000.00 812620000.00 4530000.00 149770000.00 931290000.00 8058950000.00 1317050000.00 0.00 1317050000.00 228310000.00 101890000.00 330200000.00 0.00 986850000.00 0.00 0.00 0.00 0.00 986850000.00 -1070000.00 985780000.00 0.00 0.00 0.00 0.00 572250000.00 10 17.25 17.25 0.00 0.00 17.25 17.25 Commission on sales 31430000.00 Freight charges 12710000.00 Lab consumables 20920000.00 Miscellaneous expenses 89210000.00 Packing charges 23920000.00 Power and fuel 59230000.00 Repair & Maintainance 18950000.00 Stores and spares consumed 22570000.00 Sub contracting charges 14320000.00 Travelling and conveyance 24380000.00 Commission on sales 75680000.00 Freight charges 38080000.00 Lab consumables 61720000.00 Miscellaneous expenses 251310000.00 Packing charges 66740000.00 Power and fuel 188690000.00 Repair & Maintainance 64460000.00 Stores and spares consumed 72900000.00 Sub contracting charges 41290000.00 Travelling and conveyance 70420000.00 The Company has only one reportable segment i.e.“Drugs and pharmaceutical products” as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. -830000.00 -2190000.00 -530000.00 -1120000.00